MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics dosed the first patient in a Phase 1 study of MGC030, a first-in-class antibody-drug conjugate targeting an undisclosed antigen, in patients with advanced solid tumors. The open-label dose-escalation and cohort-expansion trial will enroll up to 54 participants initially, spanning urothelial, colorectal, gastric, esophageal, and pancreatic cancers.
Key figures
- Drug Name
- MGC030
- Phase Of Trial
- Phase 1
- Trial identifier
- NCT07822399
- Drug to antibody ratio
- 4
- Dose escalation enrollment
- up to 54 participants
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.